Health Care Select Sector SPDR Fund (XLV)

NYSEARCA: XLV · Real-Time Price · USD
136.48
+0.72 (0.53%)
At close: Jul 25, 2025, 4:00 PM
136.29
-0.19 (-0.14%)
After-hours: Jul 25, 2025, 8:00 PM EDT
0.53%
Assets$33.25B
Expense Ratio0.09%
PE Ratio20.72
Shares Out247.02M
Dividend (ttm)$2.39
Dividend Yield1.75%
Ex-Dividend DateJun 23, 2025
Payout FrequencyQuarterly
Payout Ratio36.34%
Volume9,531,563
Open136.25
Previous Close135.76
Day's Range135.74 - 136.70
52-Week Low127.35
52-Week High159.64
Beta0.64
Holdings62
Inception DateDec 16, 1998

About XLV

Fund Home Page

The Health Care Select Sector SPDR Fund (XLV) is an exchange-traded fund that is based on the S&P Health Care Select Sector index. The fund tracks health care stocks from within the S&P 500 Index, weighted by market cap. XLV was launched on Dec 16, 1998 and is issued by State Street.

Asset Class Equity
Category Health
Region North America
Stock Exchange NYSEARCA
Ticker Symbol XLV
ETF Provider State Street
Index Tracked S&P Health Care Select Sector

Top 10 Holdings

55.59% of assets
NameSymbolWeight
Eli Lilly and CompanyLLY12.86%
Johnson & JohnsonJNJ8.28%
AbbVie Inc.ABBV6.84%
UnitedHealth Group IncorporatedUNH5.13%
Abbott LaboratoriesABT4.44%
Merck & Co., Inc.MRK4.29%
Thermo Fisher Scientific Inc.TMO3.64%
Intuitive Surgical, Inc.ISRG3.56%
Amgen Inc.AMGN3.37%
Boston Scientific CorporationBSX3.19%
View More Holdings

Dividends

Ex-DividendAmountPay Date
Jun 23, 2025$0.63038Jun 25, 2025
Mar 24, 2025$0.56454Mar 26, 2025
Dec 23, 2024$0.62166Dec 26, 2024
Sep 23, 2024$0.57723Sep 25, 2024
Jun 24, 2024$0.57253Jun 26, 2024
Mar 18, 2024$0.52294Mar 21, 2024
Full Dividend History

Performance

XLV had a total return of -7.39% in the past year, including dividends. Since the fund's inception, the average annual return has been 8.19%.

News

Managed care needs to improve to improve health care sector, says Mizuho's Jared Holz

Jared Holz, Mizuho health care sector strategist, joins 'The Exchange' to discuss the pain in the health care sector and if there are any opportunity plays within.

4 days ago - CNBC Television

Trump's deadline looms for Big Pharma companies facing new tariffs

'The Big Money Show' panel discusses President Donald Trump's pharmaceutical tariff strategy.

Other symbols: IBB
9 days ago - Fox Business

XLV: Life Expectancy, Patents, And A Positive Outlook Will Pave The Way

The life expectancy has increased in the U.S. and worldwide, contributing to healthcare companies retaining their patients for longer periods. Investors pay low fees to hold XLV, since the expense rat...

9 days ago - Seeking Alpha

A Historic Opportunity For REIT Investors

Today's market reminds us of 1999 in many ways. REITs were hated. Tech was loved. But afterward, REITs strongly outperformed. Here's why it could happen again.

11 days ago - Seeking Alpha

Heard on the Street: Why pharma stocks have outperformed the broader market since Trump threatened the industry with a 200% tariff

A generous grace period would give drugmakers time to sidestep most of the pain of looming duties.

Other symbols: IBB
12 days ago - WSJ

Measuring Options Activity in MRK & XLV: Healthcare Levels to Watch

Rick Ducat turns to the healthcare sector on today's options analysis. He starts with the SPDR Health Care ETF (XLV), noting the recent breakdown of a head and shoulders pattern and potential for both...

Other symbols: MRK
16 days ago - Schwab Network

XLV: The S&P 500's Most Discounted Sector? Uncover The Hidden Risk

The healthcare segment, and therefore XLV, is, in terms of relative valuations, the most attractive earning-driven sector. The strong dissonance between earnings expectations and price decline highlig...

22 days ago - Seeking Alpha

2 Healthcare Picks For Distributions And Attractive Valuations

Healthcare CEFs are under pressure from regulatory shifts, but sector defensiveness and discounted valuations can create long-term opportunities. Within the CEF structure, we also have the added benef...

Other symbols: BMEHQHUNH
24 days ago - Seeking Alpha

I've never seen a setup this negative for health care job growth, says Bancreek's Pachman

CNBC's “Power Lunch” is joined by Eric Pachman, chief analytics officer at Bancreek Capital Advisors, to discuss the U.S. labor market, whether health care jobs are in jeopardy and more.

6 weeks ago - CNBC Television

Healthcare companies are hiring. Is it time to look for growth stocks in this beaten-down sector?

The recent jobs data showed that hiring in healthcare took a big jump in May, as the stock sector has stabilized a bit after years of underperformance.

Other symbols: ABBVABTJNJLLYUNH
7 weeks ago - Market Watch

Buy America, says John Hancock's Matthew Miskin

Matthew Miskin, John Hancock Investment Management, joins 'The Exchange' to discuss markets, small and mid-caps and the industrial sector.

Other symbols: XLIXLKXLU
7 weeks ago - CNBC Television

How pet medicine stocks could cushion your healthcare investments from Trump changes

Moderna shares are seeing a boost on Monday after the US Food and Drug Administration (FDA) gave the pharmaceutical giant limited approval for its lower-dose COVID-19 vaccine. Morgan Stanley Investmen...

Other symbols: ISRGPAWZZTS
7 weeks ago - Yahoo Finance

The HealthCare Sector: A Look At Sector Earnings Trends

Looking at Q1 '25 earnings trends, the healthcare sector reported a solid quarter, even with UnitedHealth's issues. Q2 and Q3 '25 are showing lower or negative revisions, and lower levels of absolute ...

7 weeks ago - Seeking Alpha

3 Deep-Value Blue Chips: The Fat Pitch I Couldn't Resist

The worst-case scenario of big global tariffs and a severe recession is now off the table, lowering risk and supporting a new bull market. UnitedHealth offers a Buffett-style deep value opportunity af...

Other symbols: EPDUNH
7 weeks ago - Seeking Alpha

Healthcare Sector Checkup As U.S. Looks To Change Regulations

Outlook for pharma sector as Trump pushes for regulatory changes. The impact of tariffs on drugmakers.

2 months ago - Seeking Alpha

Jefferies' Michael Yee: Drug discovery could be one of the biggest beneficiaries of generative AI

Michael Yee, Jefferies senior biotech analyst, joins CNBC's 'Squawk on the Street' to discuss how AI could fuel drug discovery and development, the timeline for when pharmaceutical companies could see...

2 months ago - CNBC Television

Trump is right about drug prices. He's just going about it all wrong.

The stock market doesn't believe the president about prescription drugs.

Other symbols: IBBXBI
2 months ago - Market Watch

Final Trade: BABA, JPM, XLV, JBLU

The final trades of the day with CNBC's Melissa Lee and the Fast Money traders.

Other symbols: BABAJBLUJPM
2 months ago - CNBC Television

President Trump's EO to lower drug prices is the beginning of a long process, says Jeff Jonas

Jeff Jonas, Gabelli Funds portfolio manager, joins CNBC's 'Power Lunch' to discuss reactions to President Trump's executive order to lower drug prices, the impact to pharma companies, and more.

Other symbols: ABBVCICVSLLYMRKPFEREGN
2 months ago - CNBC Television

XLV: Trump's Drug Price Talk Revives Old Headlines, Not New Risks

The current market environment is the best I've seen in 30+ years, driven by risk management, blending technical and quantitative analysis, and ignoring most headlines. XLV, the Healthcare Sector SPDR...

2 months ago - Seeking Alpha

StemPoint's Michelle Ross breaks down navigating the pharmaceutical sector volatility

Michelle Ross, StemPoint Capital CIO, joins 'Closing Bell' to discuss health care's weak week and how to navigate pharma volatility.

Other symbols: XBI
2 months ago - CNBC Television

Defensive Sectors Continue To Lead U.S. Stock Market This Year

President Trump announced a US-UK trade deal yesterday, which may be an early sign of a thaw in the global trade war. Although the broad US stock market has rebounded sharply in recent weeks, the reco...

Other symbols: SPYXLEXLFXLIXLKXLPXLRE
2 months ago - Seeking Alpha

Final Trade: SBUX, META, XLV and BABA

The final trades of the day with CNBC's Melissa Lee and the Fast Money traders.

Other symbols: METASBUXBABA
3 months ago - CNBC Television

XLV Vs. VHT: I Prefer XLV For Its Better Downturn Resilience

The Healthcare Sector, represented by XLV and VHT ETFs, offers a defensive investment option amid current market volatility and potential recession risks. Between these two funds, I prefer XLV even be...

3 months ago - Seeking Alpha

Two Stocks To Consider During Market Unrest To Provide Income Stability

Investors should remain calm amid market volatility and consider buying during price dips, with 2025 expected to see more turbulence. Kenvue's strong brand portfolio and solid liquidity offer price st...

Other symbols: BUDJNJKVUEMOPMXLFXLK
3 months ago - Seeking Alpha